<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00117468</url>
  </required_header>
  <id_info>
    <org_study_id>DR-PGN-201</org_study_id>
    <nct_id>NCT00117468</nct_id>
  </id_info>
  <brief_title>Comparison of DR-2011 to a Progesterone Vaginal Gel for Luteal Phase Replacement</brief_title>
  <official_title>A Phase 2, Single-Center, Open-Label, Randomized, Controlled, Pharmacodynamic Study to Compare DR-2011 to a Progesterone Vaginal Gel for Luteal Phase Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duramed Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label, randomized, active-controlled study to compare DR-2011
      to progesterone vaginal gel for luteal phase replacement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2-arm, single-center, open-label, randomized, active-controlled study to compare
      the safety and efficacy of luteal phase replacement with DR-2011 to progesterone vaginal gel
      over an 18-day treatment period. Patients will also be required to use an estrogen patch
      during the course of the study. The overall study duration for each patient will be
      approximately 1Â½ months.

      Luteal phase replacement will be monitored by endometrial biopsy on Cycle Day 25 or 26. In
      addition, serum hormonal levels will be measured at screening and at designated times from
      Cycle Day 14 to 31.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adequate endometrial transformation</measure>
    <time_frame>Cycle Day 25 or 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hormone levels</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DR-2011</intervention_name>
    <description>Administered vaginally from Day 14 to Day 31</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone 8% Vaginal Gel</intervention_name>
    <description>Administered vaginally from Cycle Day 14 to Day 31</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Crinone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Not pregnant

          -  Clinically or medically-induced non-functioning or surgically removed ovaries

          -  Clinical investigator believes patient would be eligible for oocyte donation

        Exclusion Criteria:

          -  Any contraindication to progesterone or estrogen therapy

          -  Undiagnosed vaginal bleeding

          -  History of uterine fibroids or any other conditions that could adversely affect
             pregnancy success

          -  Hysterectomy

          -  Any contraindication to vaginal drug delivery systems
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duramed Protocol Chair</last_name>
    <role>Study Chair</role>
    <affiliation>Duramed Research, Inc,</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/infertility.html</url>
    <description>MedlinePlus - Infertility</description>
  </link>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>July 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2005</study_first_posted>
  <last_update_submitted>May 9, 2014</last_update_submitted>
  <last_update_submitted_qc>May 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2014</last_update_posted>
  <responsible_party>
    <name_title>Duramed Protocol Chair</name_title>
    <organization>Duramed Research, Inc.</organization>
  </responsible_party>
  <keyword>luteal phase replacement</keyword>
  <keyword>oocyte donation</keyword>
  <keyword>infertility</keyword>
  <keyword>progesterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

